The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
HOME > ORGANIZATION
ORGANIZATION
- Lifting of Ban on Online OTC Drug Sales Would “Create Situation of Grave Concern”: JMA Vice President Nakagawa
June 7, 2013
- Pros and Cons of Bungyo Should Be Reconsidered: JMARI Working Paper
June 6, 2013
- Sawai Gains Steady Market Shares of Generics in Broad Categories, Meiji Seika Pharma Strong in CNS: Survey
June 4, 2013
- ACCJ, EBC Advocate Preventive Health, Say Physicians Should Earn More by Keeping People Out of Hospitals
June 3, 2013
- Fewer Drug Makers Used Outside Organizations for MR Education and Training in FY2012: MREAC
June 3, 2013
- Drug Makers, R&D Organizations Sign Memorandum to Search Compounds for Infectious Disease Treatment: GHIT Fund
June 3, 2013
- JMA Demands Novartis Disclose Details of Internal Probe
May 31, 2013
- Actions Taken in 29 Prefectures to Eliminate Free Benefits and Labor Provided by Wholesalers: Industry FTC Reports
May 29, 2013
- Towa’s Yoshida Appointed New JGA President, Says Achieving Roadmap Goals Important
May 23, 2013
- EFPIA Japan Chairman Fauchet Prods for Review of 14 Day Prescription Limit
May 21, 2013
- New PhRMA Chairman Tells Prime Minister Abe, Pro-Innovation Policies Key to Maintaining Japanese Healthcare System
May 16, 2013
- Kyokai Kenpo Launches Trial Notification Service on Copayment Differences between Original, Generic Anti-Allergy Drugs
May 8, 2013
- Vital-Net Pres. Suzuki Tipped to Be Next President of JPWA; Number of VPs to Be Increased to 5
May 2, 2013
- Itsuro Yoshida of Towa Pharmaceutical Expected to Take Over as Next President of JGA
April 25, 2013
- “Both Sides Need to Work Harder” to Reach Agreements on Delivery Prices: Mr Nakamura of NPhA
April 23, 2013
- JPMA to Call on Its Member Companies to Ask Lecturers at Seminars Sponsored by Them for Their Permission to Disclose COI-Related Information
April 22, 2013
- JPMA Reinstates MSD K.K. as Member After 22-Month Suspension
April 22, 2013
- Tug-of-War over “Conflicts of Interest” (1): Drug Makers, Doctors Remain Divided
April 18, 2013
- APAC to Draft Roadmap for Early Drug Application and Approval in Asia
April 16, 2013
- JPMA Eyes Joint Communications Campaigns for Transparency Guidelines with JMA, JAMS
April 12, 2013
ページ
The health ministry’s key expert panel on February 15 agreed on the need to consolidate the Japanese generic sector to…
“Balance” seems to be the keyword for the next drug pricing reform in FY2024. Japan now appears ready to seek a better balance between evaluating innovative medicines and taking tough measures against companies dependent on long-listed products (LLPs) and generic…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…